Masimo (MASI) Competitors

ResMed (NYSE:RMD) and Masimo (NASDAQ:MASI) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, community ranking, institutional ownership, media sentiment, dividends, valuation and profitability.

Is RMD or MASI more profitable?

ResMed has a net margin of 25.34% compared to Masimo's net margin of 3.85%. ResMed's return on equity of 26.17% beat Masimo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ResMed	25.34%	26.17%	18.60%
Masimo	3.85%	14.98%	6.95%

Do institutionals and insiders believe in RMD or MASI?

55.0% of ResMed shares are owned by institutional investors. Comparatively, 86.0% of Masimo shares are owned by institutional investors. 0.7% of ResMed shares are owned by company insiders. Comparatively, 9.7% of Masimo shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Which has more volatility and risk, RMD or MASI?

ResMed has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500. Comparatively, Masimo has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500.

Does the media refer more to RMD or MASI?

In the previous week, ResMed had 30 more articles in the media than Masimo. MarketBeat recorded 43 mentions for ResMed and 13 mentions for Masimo. Masimo's average media sentiment score of 1.05 beat ResMed's score of 0.85 indicating that Masimo is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ResMed	23 Very Positive mention(s)	6 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Masimo	10 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate RMD or MASI?

ResMed presently has a consensus target price of $258.83, suggesting a potential upside of 9.45%. Masimo has a consensus target price of $194.80, suggesting a potential upside of 21.02%. Given Masimo's stronger consensus rating and higher probable upside, analysts plainly believe Masimo is more favorable than ResMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ResMed	1 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.60
Masimo	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Which has preferable earnings & valuation, RMD or MASI?

ResMed has higher revenue and earnings than Masimo. Masimo is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ResMed	$5.02B	6.92	$1.02B	$8.91	26.54
Masimo	$2.09B	4.15	$81.50M	-$5.70	-28.24

Does the MarketBeat Community favor RMD or MASI?

Masimo received 28 more outperform votes than ResMed when rated by MarketBeat users. Likewise, 63.79% of users gave Masimo an outperform vote while only 52.65% of users gave ResMed an outperform vote.

Company	Underperform	Outperform
ResMed	Outperform Votes 437 52.65%	Underperform Votes 393 47.35%
Masimo	Outperform Votes 465 63.79%	Underperform Votes 264 36.21%

Summary

ResMed beats Masimo on 10 of the 19 factors compared between the two stocks.